Eyepoint Pharmaceuticals (EYPT) Projected to Release Earnings on Wednesday

Eyepoint Pharmaceuticals (NASDAQ:EYPT) will likely be posting its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Eyepoint Pharmaceuticals to post earnings of ($0.92) per share and revenue of $0.3860 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 8:30 AM ET.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative net margin of 3,566.63% and a negative return on equity of 110.54%. The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.35 million. On average, analysts expect Eyepoint Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Eyepoint Pharmaceuticals Price Performance

NASDAQ:EYPT opened at $12.25 on Monday. Eyepoint Pharmaceuticals has a 52 week low of $9.40 and a 52 week high of $19.11. The stock has a market capitalization of $1.03 billion, a PE ratio of -3.50 and a beta of 1.76. The stock’s 50-day moving average price is $13.18 and its 200-day moving average price is $13.87.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Several institutional investors have recently bought and sold shares of EYPT. Russell Investments Group Ltd. purchased a new stake in Eyepoint Pharmaceuticals during the 3rd quarter worth approximately $76,000. Tower Research Capital LLC TRC lifted its position in shares of Eyepoint Pharmaceuticals by 218.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after acquiring an additional 5,967 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of Eyepoint Pharmaceuticals by 20.6% in the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after acquiring an additional 794 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Eyepoint Pharmaceuticals in the fourth quarter worth approximately $98,000. Finally, Raymond James Financial Inc. increased its position in shares of Eyepoint Pharmaceuticals by 11.0% during the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after purchasing an additional 1,177 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EYPT has been the subject of a number of analyst reports. Guggenheim reaffirmed a “buy” rating and issued a $68.00 price target on shares of Eyepoint Pharmaceuticals in a report on Wednesday, June 24th. Royal Bank Of Canada cut their price objective on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Chardan Capital upped their target price on Eyepoint Pharmaceuticals from $29.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Friday, July 17th. Finally, Cantor Fitzgerald began coverage on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, July 8th. They issued an “overweight” rating and a $47.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.75.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.